Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
81 hedge funds and large institutions have $47M invested in Kezar Life Sciences in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 14 closing their positions.
2,883% more call options, than puts
Call options by funds: $179K | Put options by funds: $6K
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
0.8% less ownership
Funds ownership: 7.63% → 6.83% (-0.8%)
1% less funds holding
Funds holding: 82 → 81 (-1)
29% less capital invested
Capital invested by funds: $66M → $47M (-$19M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$601K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$582K |
| 3 |
Two Sigma Advisers
New York
|
+$573K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$537K |
| 5 |
Two Sigma Investments
New York
|
+$473K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.11M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.62M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.24M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$866K |
| 5 |
Goldman Sachs
New York
|
-$828K |
KZR Hedge Fund Activity: Q4 2023 in Review
81 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2023, worth a combined $47M — down 29% from $66M a quarter earlier.
Fund positioning in KZR was balanced in Q4 2023: 14 funds opened new positions, 14 closed out, 27 added to existing stakes and 26 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $601K. The largest seller was OrbiMed, cutting an estimated $3.11M.
- 81 institutional investors held Kezar Life Sciences (KZR) as of Q4 2023, down from 82 in Q3 2023.
- Funds reported $47M of Kezar Life Sciences stock for Q4 2023, down 29% quarter-over-quarter.
- 14 funds opened new Kezar Life Sciences positions in Q4 2023 and 14 closed out, a net change of 0 holders.
- The largest Kezar Life Sciences buyer in Q4 2023 was Renaissance Technologies, an estimated $601K added.
- The largest Kezar Life Sciences seller in Q4 2023 was OrbiMed, an estimated $3.11M sold.
Based on aggregated 13F filings for Q4 2023.